ストックスクリーナーアプリを入手
3.155
0.00%
0.005
Replimune Group Inc (REPL) 最新ニュース
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc. - GlobeNewswire
How to escape a deep drawdown in Replimune Group Inc.Free Growth Based Investment Plan Guidance - Newser
Using portfolio simulators with Replimune Group Inc. includedFree Buy Low Sell High Stock Watch - Newser
Order flow analysis tools used on Replimune Group Inc. Buy/Sell Zone Confirmation Technical Analysis - Newser
Securities Litigation in Biotech: Navigating the Replimune Crisis and Its Broader Implications - AInvest
Regulatory Setbacks and Legal Risks: Replimune Group's Turbulent Path in the Biotech Sector - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - WV News
Important Notice to Long-Term Shareholders of Alto - GlobeNewswire
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Leerink Partnrs Expects Lower Earnings for Replimune Group - Defense World
REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire
Replimune Group (NASDAQ:REPL) Cut to “Underperform” at BMO Capital Markets - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Equal Weight” at Barclays - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Neutral” at HC Wainwright - Defense World
REPLIMUNE GROUP, INC. (NASDAQ: REPL) INVESTOR ALERT Investors With Large Losses in Replimune Group, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - ACCESS Newswire
[REPL] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. Investors - TradingView
Potential Securities Fraud: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Is Replimune Group Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Ongoing Replimune Group, Inc. (REPL) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending - GlobeNewswire
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline - FinancialContent
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL - Morningstar
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Replimune Group (NASDAQ:REPL) Cut to “Hold” at Leerink Partnrs - Defense World
Replimune Group (NASDAQ:REPL) Cut to Hold at Cantor Fitzgerald - Defense World
Shareholder Alert: Robbins LLP Informs Investors of The Replimune Group, Inc. Class Action - ACCESS Newswire
REPL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Replimune Group and the Biotech Litigation Time Bomb: Evaluating Risks in a High-Stakes Sector - AInvest
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL - Business Wire
Shareholders Alert: Investigation Into Replimune Group, Inc. (REPL)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC - GlobeNewswire
REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire
REPL ACTIVE INVESTIGATION: Lost Money on Replimune Group, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors - GlobeNewswire
What analysts say about Replimune Group Inc. stockExceptional trading results - Autocar Professional
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action InvestigationREPL - Morningstar
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor ConcernsHagens Berman - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Replimune Group (REPL.O) Surges 34%—What’s Behind the Sharp Intraday Move? - AInvest
Iovance climbs after FDA rejection for Replimune’s skin cancer drug - MSN
Replimune Group Stock Drops Significantly on News of FDA Complete Response LetterKehoe Law Firm, P.C. Investigating Securities Claims on Behalf of InvestorsREPL - ACCESS Newswire
Replimune (REPL) Shares Rebound Despite FDA Setback - GuruFocus
Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha
Fraud Investigation Opened: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) on Behalf of Shareholders - ACCESS Newswire
Replimune Viral-Based Therapy for Melanoma Rejected By FDA - Inside Precision Medicine
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application - MSN
What drives Replimune Group Inc. stock priceExplosive trading opportunities - Autocar Professional
Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum
Replimune says FDA rejected its lead drug for skin cancer - MSN
0.47%
0.71%
大文字化:
|
ボリューム (24 時間):